Shirish M. Gadgeel
University of Michigan
438 Papers
1.5K Citations
Shirish M. Gadgeel is an academic researcher from University of Michigan. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 56, co-authored 347 publications. Previous affiliations of Shirish M. Gadgeel include Wayne State University & Henry Ford Health System.
Chat about Author
Papers
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish M. Gadgeel,Delvys Rodriguez-Abreu,Giovanna Speranza,Emilio Esteban,Enriqueta Felip,Manuel Domine,Rina Hui,Maximilian Hochmair,Philip Clingan,Steven Francis Powell,Susanna Yee Shan Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Edward B. Garon,Silvia Novello,Belén Rubio-Viqueira,Michael Boyer,Takayasu Kurata,Jhanelle E. Gray,J. Yang,Tuba Bas,M. Catherine Pietanza,Marina Chiara Garassino +25 more
TL;DR: First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon,Benjamin Besse,Benjamin Besse,Todd M. Bauer,Enriqueta Felip,Ross A. Soo,D. Ross Camidge,Rita Chiari,Alessandra Bearz,Chia-Chi Lin,Shirish M. Gadgeel,Gregory J. Riely,Eng Huat Tan,Takashi Seto,Leonard P. James,Jill S. Clancy,Antonello Abbattista,Jean-Francois Martini,Joseph Chen,Gerson Peltz,Holger Thurm,Sai-Hong Ignatius Ou,Alice T. Shaw +22 more
TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
723
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel,Leena Gandhi,Gregory J. Riely,Alberto Chiappori,Howard West,Michele C. Azada,Peter N. Morcos,Ruey Min Lee,Linta Garcia,Li Yu,Frederic Boisserie,Laura Di Laurenzio,Sophie Golding,Jotaro Sato,Shumpei Yokoyama,Tomohiro Tanaka,Sai-Hong Ignatius Ou +16 more
TL;DR: Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.
701
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw,Leena Gandhi,Shirish M. Gadgeel,Gregory J. Riely,Jeremy Cetnar,Howard West,D. Ross Camidge,Mark A. Socinski,Alberto Chiappori,Tarek Mekhail,Bo H. Chao,Hossein Borghaei,Kathryn A. Gold,Ali Zeaiter,Walter Bordogna,Bogdana Balas,Oscar Puig,Volkmar Henschel,Sai-Hong Ignatius Ou +18 more
TL;DR: Alectinib showed clinical activity and was well tolerated in patients with ALK-positive NSCLC who had progressed on crizotinib and could be a suitable treatment for patients with AlK- positive disease who have progressed oncrizotin ib.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
Pasi A. Jänne,Gregory J. Riely,Shirish M. Gadgeel,Rebecca S. Heist,Sai-Hong Ignatius Ou,Jose M. Pacheco,Melissa Lynne Johnson,Joshua K. Sabari,Konstantinos Leventakos,Edwin Yau,Lyudmila Bazhenova,Marcelo V. Negrao,Nathan A. Pennell,Jun Zhang,Kenna Anderes,Hirak Der-Torossian,Thian Kheoh,Karen Velastagui,Xiao Qiang Yan,James G. Christensen,Richard C. Chao,Alexander I. Spira +21 more
TL;DR: In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals.
565